By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Juno Therapeutics 

307 Westlake Avenue North
Suite 300
Seattle  Washington    U.S.A.
Phone: 206-582-1600 Fax: n/a


SEARCH JOBS

Juno is a clinical-stage company that brings together three of the world’s leading cancer centers – Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and Seattle Children’s Research Institute – in unique partnership to advance a broad pipeline of breakthrough immunotherapies. With one of the largest ever Series A investments for a biotech startup, Juno will build on the foundation of novel immunotherapies to develop two distinct and complementary platforms – CARs and TCRs.

The CAR technology is designed to target cell surface antigens that are expressed on cancer cells. In addition, the high-affinity TCR technology can also detect alterations in intracellular proteins present in tumor cells. These treatments have the potential to reduce longer-term toxicities associated with chemotherapeutics. Our goal is to drive multiple product candidates in select hematologic and solid tumor cancers to FDA licensure. Each product candidate has the potential to treat a variety of high-risk cancers.

YEAR FOUNDED:

August 5, 2013

LEADERSHIP:

Founders: : Hans Bishop, Richard Klausner, and Robert Nelsen

CEO and Co-founder: Hans Bishop

JOBS:

Please click here for job opportunities.

CLINICAL TRIAL:

Please click here for clinical trial information.


FOLLOW JUNO:



Key Statistics


Email: Info@junotherapeutics.com
Ownership: Private

Web Site: Juno
Employees: n/a
Symbol: JUNO
 



Industry
Biotechnology






Company News
Latest Deaths in Juno (JUNO) Trial Puts Unwanted Limelight on the FDA 11/28/2016 5:58:07 AM
Juno (JUNO) Halts CAR-T Trial for Second Time Following Additional Patient Deaths 11/23/2016 6:21:00 AM
Despite Scarce Resources, Juno (JUNO) Still Impressed With Its Expansion in China 11/11/2016 6:37:09 AM
Juno (JUNO) Reports Third Quarter 2016 Financial Results 11/10/2016 3:09:00 PM
Juno (JUNO) Was Being Wooed to the Big Apple But Here's Why It's Staying in Seattle 11/7/2016 7:16:50 AM
Juno (JUNO) To Report Third Quarter 2016 Financial Results On Wednesday, November 9 11/3/2016 11:49:56 AM
Watch Out Juno (JUNO) and Kite Pharma (KITE): Novartis AG (NVS) Clearly Not Done With CAR-T 10/25/2016 6:12:56 AM
Washington State's Biotech Industry is Not Only Lagging, But Regressing Says Juno (JUNO) CEO 10/5/2016 6:11:38 AM
Investors Beware: Thin CAR-T Data Could Make or Break Juno (JUNO) and Kite Pharma (KITE) 9/22/2016 7:05:48 AM
Juno (JUNO) Spends Big Bucks on R&D, Even Though Approval Won't Come Until 2018 9/22/2016 7:00:17 AM
12345678910...
//-->